Since the therapy is going to be a "conditional market approval" all of its participants will have to be recorded in a database and subject to possible follow ups, notified if sh*t goes bad, etc. by necessity.
Now, I can't find any info that wouldn't be in Japanese about the matter, but I could very easily see them not taking international patients for this reason. I could easily see them viewing international patients as too much of a liability given the record-keeping requirements, conditional approval, etc. and just refusing them outright. Ostensibly, this is just an extended clinical trial that is available to the public; consider that clinical trials are generally restricted to citizens or permanent residents of the country in question.
A lot of people here just can't see that perspective because they genuinely think this is something that is going to rake in billions, win nobel prizes, etc. and there's just no way the Japanese would do that — but that is incredibly naive.
So consider the following:
Tsuji and Shiseido are both going to be conditional approvals granting seven years before you have to provide necessary data to pass phase 3.
Let's say they both hit the market in 2020. It could very easily be 2027 before anyone outside of Japan can get it.